Estados Unidos · Plataformas y datos · MarketBeat

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Publicado por MarketBeat · Estados Unidos hace 2 h

Oruka Therapeutics (NASDAQ:ORKA) reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis.…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

También te puede interesar

Is a Stock Market Crash Coming? What History Says a $10,000 Investment in an S&P 500 ETF Could Be Worth at the End of 2027.

Brixmor Property raises dividend by 7.3% to $0.33 a share

MSCI general counsel Robert Gutowski sells $1.48M in stock

What gave this city its ‘best place to retire’ crown? You can actually afford to live there.

Banks are locking AI agents out, Hashgraph CIO Gregg Bell says blockchain is the way back in

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study

Compartir

También te puede interesar

Is a Stock Market Crash Coming? What History Says a $10,000 Investment in an S&P 500 ETF Could Be Worth at the End of 2027.

Brixmor Property raises dividend by 7.3% to $0.33 a share

MSCI general counsel Robert Gutowski sells $1.48M in stock

What gave this city its ‘best place to retire’ crown? You can actually afford to live there.

Banks are locking AI agents out, Hashgraph CIO Gregg Bell says blockchain is the way back in

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030